|
| | | | | | | | | | | | |
| Brand | Generic | Indication | MOA | Approval | Economics | Admin | IP | | Price | 88.86 | |
| Empaveli | pegcetacoplan | PNH | C3 | 5/14/2021 | | subcutaneous infusion | | | Shares | 116.457008 | Q123 |
| Syfovre | pegcetacoplan | Geographic Atrophy | C3 | 2/1/2023 | SOBI | intravitreal | | | MC | 10348.36973088 | |
| | | | | Phase | | | | | Cash | 766.358 | Q123 |
| APL-2006 | | | C3/VEGF | | | | | | Debt | 92.809 | Q123 |
| APL-1030 | | | CNS active | Preclinical | | | | | EV | 9674.82073088 | |
| | | | siRNA | IND | | | | | AD | 2486.638 | Q123 |
| | | | | | | | | | | | |
| | | | | | 5/4/23: Q123 results | | | | Founded | 2009 | |
| | | | | | 5/3/23: investor conference | | | | | | |
| | | | | | 4/27/23: Q123 call date | | | | CEO: Cedric Francois | | |
| | | | | | 4/24/23: MERIDIAN ALS study discontinued | | | | CDO: Jeff Eisele | | |
| | | | | | 4/23/23: ARVO presentation of DERBY and OAKS | | | | CMO: Federico Grossi | | |
| | | | | | 4/21/23: Validation of Canadian, Australian, UK, Switzerland GA MAAs | | | | CCO: Adam Townsend | | |
| | | | | | 4/17/23: endorsement for GA awareness | | | | CMO: Caroline Baumal | | |
| | | | | | 4/6/23: inducements | | | | | | |
| | | | | | 3/6/23: inducements | | | | | | |